• N. Conlon and I. Royzman, “INSIGHT: FDA Approves First-Ever RNAi-based Therapy,” Bloomberg Law (August 28, 2018)
  • N. Conlon and R. McNeill, “Reform Law Would Allow For Quick Challenges to Patents,” The National Law Journal (May 9, 2011)
  • N. Conlon and R. McNeill, “Patent Legislation - Meeting the Challenges of Reform?” Intellectual Property Today (January 28, 2011)


  • N. Conlon et al., “Tetramers Reveal IL-17-Secreting CD4+ T Cells That Are Specific for U1-70 in Lupus and Mixed Connective Tissue Disease, PNAS, 112 (10): 3044-49 (2015)
  • N. Conlon et al., “Characterization of Influenza Vaccine Immunogenicity Using Influenza Antigen Microarrays,” PLoS One, 8(5): e64555 (2013)
  • N. Conlon et al., “Self-Antigen Recognition by Follicular Lymphoma B-Cell Receptors,” Blood, 120(20): 4182-90 (2012)
  • N. Conlon et al., “Editor's Note: What We Can Do With What We Inherit: Shaping the Future of Stem Cell Research and Policy,” Stan. J. L. Sci. & Pol'y, 3: 36-41 (2010)
  • N. Conlon et al., “The U1-snRNP Complex: Structural Properties Relating to Autoimmune Pathogenesis in Rheumatic Diseases,” Immunol. Rev., 233(1): 126-45 (2010)
  • N. Conlon et al., “Elucidation of the Interleukin-15 Binding Site on its Alpha Receptor by NMR,” Biochemistry, 46(33): 9453-61 (2007)
  • N. Conlon et al., “How a Single T Cell Receptor Recognizes Both Self and Foreign MHC,” Cell, 129(1): 135-46 (2007)
  • N. Conlon et al., “Engineering and Characterization of a Stabilized Alpha1 /Alpha2 Module of the Class I Major Histocompatibility Complex Product Ld,” J. Bio. Chem., 281(35): 25734-44 (2006)